Drugs · acquisition-cost intelligence
Carbamazepine
· ingredient carbamazepineCarboxamide derivatives· CARBAMAZEPINE 100 mg/5mL; CARBAMAZEPINE 200 mg/10mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.10059
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other carbamazepine products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Epitol | $0.12396 | +$0.02340 |
| Carbamazepine | $0.12396 | +$0.02340 |
| Carbamazepine | $0.12396 | +$0.02340 |
| Carbamazepine | $0.12396 | +$0.02340 |
| Carbamazepine | $0.23438 | +$0.13380 |
| Carbamazepine ER | $0.49118 | +$0.39060 |
| Carbamazepin | $0.60091 | +$0.50030 |
| carbamazepine | $1.03 | +$0.92760 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 1% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.